The results of a study on the safety of the dietary supplement neurouridine in patients with nonspecific low back pain (MULTINEURO-2)

Yakupov E.Z.; Troshina Y.V.; Gainutdinova R.R.; Kashapova A.O.

doi:https://doi.org/10.17116/jnevro202112103152

Yakupov E.Z.

Scientific Research Medical Complex «Your Health»;
Kazan State Medical University

Troshina Y.V.

Scientific Research Medical Complex «Your Health»;
Kazan State Medical University

Gainutdinova R.R.

Scientific Research Medical Complex «Your Health»

Kashapova A.O.

Scientific Research Medical Complex «Your Health»

The results of a study on the safety of the dietary supplement neurouridine in patients with nonspecific low back pain (MULTINEURO-2)

Authors:

Yakupov E.Z., Troshina Y.V., Gainutdinova R.R., Kashapova A.O.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(3): 52‑56

DOI: 10.17116/jnevro202112103152

Read: 13531 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Yakupov EZ, Troshina YV, Gainutdinova RR, Kashapova AO. The results of a study on the safety of the dietary supplement neurouridine in patients with nonspecific low back pain (MULTINEURO-2). S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(3):52‑56. (In Russ.)
https://doi.org/10.17116/jnevro202112103152

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

OBJECTIVE

To assess the efficacy and safety of high (300 mg) doses of the biologically active additive neurouridin (Unifarm) as part of complex therapy of patients with nonspecific low-back pain.

MATERIAL AND METHODS

Fifty patients (30 in the main group and 20 patients in the control group) were studied using a visual analogue scale (VAS), data from a general clinical analysis of blood and urine, a wide range of biochemical parameters, including liver function tests, glucose levels, creatinine, electrolyte levels.

RESULTS AND CONCLUSION

The positive effect of treatment with neurouridin on the dynamics of changes in pain according to the VAS was noted, a dose-dependent effect was revealed: patients at higher doses (300 mg of uridine monophosphate) showed a more significant regression of pain symptoms compared to standard doses. During the study, there were no serious adverse events allergic reactions. No clinically significant deviations of laboratory parameters were recorded

Keywords:

low back pain

safety of high-doses of uridine monophosphate

neurouridin

Authors:

Yakupov E.Z.

Scientific Research Medical Complex «Your Health»;
Kazan State Medical University

Troshina Y.V.

Scientific Research Medical Complex «Your Health»;
Kazan State Medical University

Gainutdinova R.R.

Scientific Research Medical Complex «Your Health»

Kashapova A.O.

Scientific Research Medical Complex «Your Health»

Received:

25.01.2021

Accepted:

27.01.2021

Close metadata

References:

Yakupov EZ. Adjuvant therapy of pain syndromes: possibilities of using nucleotides. S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2019;119(10):141-145. (In Russ.). https://doi.org/10.17116/jnevro2019119101141
Yakupov EZ. Treatment of the pain syndroms. New look at the old problem? Medical Sovet. 2019;12:50-54. (In Russ.). https://doi.org/10.21518/2079-701X-2019-12-20-24
Goldberg H, Mibielli MA, Nunes CP, et al. A double-blind, randomized, comparative study of the use of a combination of uridine triphosphate trisodium, cytidine monophosphate disodium, and hydroxocobalamin, versus isolated treatment with hydroxocobalamin, in patients presenting with compressive neuralgias. J Pain Res. 2017;10:397-404. https://doi.org/10.2147/JPR.S123045
Negrão L, Almeida P, Alcino S, et al. Effect of the combination of uridine nucleotides, folic acid and vitamin B12 on the clinical expression of peripheral neuropathies. Pain Manag. 2014;4(3):191-196. https://doi.org/10.2217/pmt.14.10
Yakupov EZ, Troshina YV, Kashapova AO, et al. Results of open observation research of multymodal effects and safety BAS «Neurouridin» in patients with non-specific low back pain ( MULTINEURO-1). S.S. Korsakov Journal of Neurology and Psychiatry = Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2020;120(9):53-59. (In Russ.). https://doi.org/10.17116/jnevro202012009153
Ando RD, Mehesz B, Gyires K, et al. A comparative analysis of the activity of ligands acting at P2X and P2Y receptor subtypes in models of neuropathic, acute and inflammatory pain. Br J Pharmacol. 2010;159(5):1106-1117. https://doi.org/10.1111/j.1476-5381.2009.00596.x
Kondo DG, Sung YH, Hellem TL, et al. Open-label uridine for treatment of depressed adolescents with bipolar disorder. J Child Adolesc Psychopharmacol. 2011;21(2):171-175. https://doi.org/10.1089/cap.2010.0054
Kypson J, Hait G. Effects of uridine and inosine on glucose metabolism in skeletal muscle and activated lipolysis in adipose tissue. J Pharmacol Exp Ther. 1976;199(3):565-574.